Literature DB >> 9233710

Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture.

M Boeckh1, G M Gallez-Hawkins, D Myerson, J A Zaia, R A Bowden.   

Abstract

In a prospective longitudinal study, detection of cytomegalovirus (CMV) DNA in plasma (plasma polymerase chain reaction [PCR]) was compared with PCR of CMV DNA in peripheral blood leukocytes (PBL PCR), the CMV pp65 antigenemia assay, and viral cultures from blood, urine, and throat of 29 patients, 14 of whom received pp65 antigenemia-guided early ganciclovir treatment and 15 of whom received ganciclovir at engraftment. Among 328 blood samples tested by all methods, PBL PCR was the most sensitive test, followed by the pp65 antigenemia assay, plasma PCR, and viremia. In the 14 patients who received pp65 antigenemia-guided early treatment, the incidence of PBL PCR, pp65 antigenemia, plasma PCR, and viremia before day 100 was 79%, 79%, 71%, and 27%, respectively, with a median day of onset of day 32, 42, 45, and 51, respectively. Nine patients (64%) became positive by PBL PCR, pp65 antigenemia, and plasma PCR. Of 15 patients who were treated with ganciclovir at engraftment, 12 (80%) became positive by PBL PCR, plasma PCR, and/or pp65 antigenemia while receiving ganciclovir; 3 (20%) had breakthrough infection with all three methods, including 2 with high-grade antigenemia (more than three positive cells in duplicate staining); none of these patients subsequently developed positive CMV cultures or disease. In 49 specimens, PBL PCR and/or pp65 antigenemia assay could not be performed because of insufficient neutrophil counts. In conclusion, the sensitivity of plasma PCR is significantly lower than that of PBL PCR but similar to that of the pp65 antigenemia assay. Plasma PCR may be particularly useful in clinical situations in which a less sensitive and possibly more specific assay is warranted or in which leukocyte counts are inadequate to perform cell-based assays.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9233710     DOI: 10.1097/00007890-199707150-00020

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  38 in total

1.  Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation.

Authors:  U Machida; M Kami; T Fukui; Y Kazuyama; M Kinoshita; Y Tanaka; Y Kanda; S Ogawa; H Honda; S Chiba; K Mitani; Y Muto; K Osumi; S Kimura; H Hirai
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

2.  High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay.

Authors:  Lutz Von Müller; Walter Hampl; Joachim Hinz; Helga Meisel; Angela Reip; Elisabeth Engelmann; Regine Heilbronn; Barbara Gärtner; Oliver Krämer; Hermann Einsele; Holger Hebart; Tatjana Ljubicic; Jürgen Löffler; Thomas Mertens
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

3.  Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients.

Authors:  A M Caliendo; K St George; S Y Kao; J Allega; B H Tan; R LaFontaine; L Bui; C R Rinaldo
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

4.  Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR.

Authors:  Michael Boeckh; MeeiLi Huang; James Ferrenberg; Terry Stevens-Ayers; Laurence Stensland; W Garrett Nichols; Lawrence Corey
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

5.  Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.

Authors:  Margaret L Green; Wendy Leisenring; Daniel Stachel; Steven A Pergam; Brenda M Sandmaier; Anna Wald; Lawrence Corey; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-07       Impact factor: 5.742

6.  A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Seung Tae Kim; Mark H Lee; Sung Yong Kim; Seok Jin Kim; Dong Hwan Kim; Jun Ho Jang; Kihyun Kim; Won Seog Kim; Chul Won Jung
Journal:  Int J Hematol       Date:  2010-05-08       Impact factor: 2.490

Review 7.  Prevention of Transfusion-Transmitted Cytomegalovirus Infections: Which is the Optimal Strategy?

Authors:  Malte Ziemann; Holger Hennig
Journal:  Transfus Med Hemother       Date:  2013-12-19       Impact factor: 3.747

8.  Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma.

Authors:  Marianne Leruez-Ville; Marie Ouachée; Richard Delarue; Anne-Sophie Sauget; Stéphane Blanche; Agnès Buzyn; Christine Rouzioux
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

Review 9.  Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants.

Authors:  Ellen Meijer; Greet J Boland; Leo F Verdonck
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

10.  Institution affects association between CMV seronegative graft and leukemic relapse after pediatric HCT.

Authors:  Carolyn E Behrendt; Ryotaro Nakamura; John Zaia
Journal:  Biol Blood Marrow Transplant       Date:  2009-08-03       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.